Neurocrine patents expiration
1. Ingrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(6 years from now) | |
| US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
| US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
| US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
| US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
| US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
| US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
| US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(3 years from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(14 years from now) | |
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(14 years from now) | |
| US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(14 years from now) | |
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(15 years from now) | |
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
| New Indication(I-925) | Aug 18, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; A method of treating huntington's chorea
Dosage: CAPSULE;ORAL
INGREZZA family patents
2. Ongentys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(3 years from now) | |
| US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(4 years from now) | |
| US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(2 years from now) | |
| US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(3 years from now) | |
| US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(5 years from now) | |
| US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL
ONGENTYS family patents